[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Immuntherapie von Kopf-Hals-Tumoren : Highlights der ASCO-Jahrestagung 2019.
Antineoplastic agents
Head and neck neoplasms
Human papilloma viruses
Squamous cell carcinoma
Tumor antibodies
Journal
HNO
ISSN: 1433-0458
Titre abrégé: HNO
Pays: Germany
ID NLM: 2985099R
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
pubmed:
16
10
2019
medline:
18
12
2019
entrez:
16
10
2019
Statut:
ppublish
Résumé
In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO). All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019 were evaluated for relevance and the most interesting studies were summarized. The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). The EAGLE study on durvalumab ± tremelimumab in second-line therapy did not demonstrate any improvement in response rates or overall survival compared to standard therapy. In addition, several new immunotherapeutic approaches and combinations were presented. The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.
Sections du résumé
BACKGROUND
BACKGROUND
In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were a highlight at this year's meeting of the American Society of Clinical Oncology (ASCO).
MATERIALS AND METHODS
METHODS
All abstracts and presentations on immunotherapy of head and neck tumors presented at ASCO 2019 were evaluated for relevance and the most interesting studies were summarized.
RESULTS
RESULTS
The Keynote-048 study showed an improvement in overall survival with pembrolizumab monotherapy for patients with measurable programmed cell death ligand 1 (PD-L1) expression according to the combined positive score (CPS), and for the whole cohort with the combination of pembrolizumab and platin/5-fluorouracil (FU). The EAGLE study on durvalumab ± tremelimumab in second-line therapy did not demonstrate any improvement in response rates or overall survival compared to standard therapy. In addition, several new immunotherapeutic approaches and combinations were presented.
CONCLUSION
CONCLUSIONS
The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.
Identifiants
pubmed: 31612261
doi: 10.1007/s00106-019-00761-8
pii: 10.1007/s00106-019-00761-8
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
905-911Références
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Ann Oncol. 2014 Mar;25(3):682-8
pubmed: 24567516
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Cancer Res. 2018 May 1;78(9):2383-2395
pubmed: 29440171
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
HNO. 2016 Oct;64(10):700-7
pubmed: 27624904
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740